Hyperprogression after nivolumab for the treatment of melanoma
Indian J Dermatol Venereol Leprol
.
2023 Jul-Aug;89(4):616-617.
doi: 10.25259/IJDVL_160_2021.
Authors
Alexandra Perea Polak
1
,
Silvestre Martínez García
1
,
Daniel Jesus Godoy Díaz
1
Affiliation
1
Department of Dermatology, Hospital Regional Universitario de Málaga, Plaza Hospital Civil, Málaga, Spain.
PMID:
35593296
DOI:
10.25259/IJDVL_160_2021
No abstract available
MeSH terms
Antineoplastic Combined Chemotherapy Protocols
Humans
Melanoma* / drug therapy
Nivolumab* / adverse effects
Substances
Nivolumab